From the Research
No, there is currently no commercially available sublingual version of sermorelin approved for medical use. Sermorelin is a growth hormone-releasing hormone (GHRH) analog that is typically administered via subcutaneous injection. The peptide structure of sermorelin makes it vulnerable to degradation in the digestive tract and when placed under the tongue, which significantly reduces its bioavailability through these routes. The molecular size and chemical properties of sermorelin prevent effective absorption through the oral mucosa. While some compounding pharmacies might claim to offer sublingual formulations, these have not been proven to deliver effective blood levels of the medication comparable to injectable forms. Patients seeking sermorelin therapy should use the established subcutaneous injection method, which typically involves daily injections of 100-500 mcg before bedtime to align with the body's natural growth hormone release patterns. This route ensures the peptide reaches the bloodstream intact and can effectively stimulate the pituitary gland to release growth hormone, as supported by studies such as 1. Key points to consider include:
- Sermorelin's effectiveness in promoting growth in children with idiopathic growth hormone deficiency, as seen in studies like 1
- The importance of proper administration to ensure bioavailability and effectiveness
- The lack of evidence supporting sublingual formulations as a viable alternative to subcutaneous injection
- The need for careful consideration of individual patient needs and medical history when determining the best course of treatment, as discussed in studies like 2